EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Methadone versus other opioids for refractory malignant bone pain: a pilot randomised controlled study

Merlina Sulistio, Alexandra Gorelik, Hoong Jiun Tee, Robert Wojnar, David Kissane, Natasha Michael

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-024-08706-w ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Merlina Sulistio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cabrini Health, Melbourne, VIC, 3144, Australia. msulistio@cabrini.com.au. Hauptthemen laut MEDLINE: Analgesics, Opioid, Methadone, Cancer Pain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cabrini Foundation, Monash University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Refractory cancer-induced bone pain (CIBP) affects a patient’s functional capacity and quality of life, but there is limited evidence to guide opioid choice. We assessed the feasibility, tolerability and possible efficacy of methadone rotation (MR) compared to other opioid rotations (OOR) in this cohort.

Methods

Adults with CIBP and worst pain intensity ≥ 4/10 and/or opioid toxicity graded ≥ 2 on the Common Terminology Criteria for Adverse Events were randomised 1:1 to methadone or another opioid rotation. Standardised assessment tools were used at pre-defined study time points up to 14 days.

Results

Of 51 eligible participants, 38 (74.5%) consented, and 29 (76.3%, MR: 14, OOR: 15) completed the fourteen days follow-up post-opioid rotation. Both groups displayed significant reduction in average (MR: d = − 1.2, p = 0.003, OOR: d = − 0.8, p = 0.015) and worst pain (MR: d = − 0.9, p = 0.042, OOR: d = − 0.6, p = 0.048) and total pain interference score (MR: d = − 1.1, p = 0.042, OOR: d = − 0.7, p = 0.007). Oral morphine equivalent daily dose was reduced significantly in MR compared to the OOR group ( d = − 0.8, p = 0.05). The incidence of opioid-related adverse events following MR was unchanged but lower in the OOR group ( d = 0.9, 95% CI 0.1,1.7, p = 0.022). There were no within-group or between-group differences in satisfaction with analgesia at the end of the study.

Conclusion

This pilot study demonstrated that MR and OOR in patients with refractory CIBP are feasible, safe and acceptable to patients. Appropriately powered multi-centre randomised controlled studies are needed to confirm the efficacy of MR and OOR in this cohort.

Trial registration

ACTRN12621000141842 registered 11 February 2021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidMethadoneCancer PainHumansPilot ProjectsMaleFemaleMiddle AgedAgedBone NeoplasmsPain MeasurementAdultFeasibility StudiesQuality of LifeIntractable Pain

Stichwörter der Autor:innen

Bone painMethadoneOpioidPain controlRefractory pain

Substanzen

Analgesics, OpioidMethadone

Autor:innen und Institutionen

  • Cabrini Health, Melbourne, VIC, 3144, Australia. msulistio@cabrini.com.au.
  • Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia. msulistio@cabrini.com.au.
  • School of Medicine, University of Notre Dame Australia, Fremantle, Australia. msulistio@cabrini.com.au.
  • Musculoskeletal Health and Wiser Healthcare Units, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
  • Cabrini Health, Melbourne, VIC, 3144, Australia.

Förderung

  • Cabrini Foundation
  • Monash University

Zitieren

APA

Sulistio, M., Gorelik, A., Tee, H. J., Wojnar, R., Kissane, D., & Michael, N. (2024). Methadone versus other opioids for refractory malignant bone pain: a pilot randomised controlled study. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08706-w

Vancouver

Sulistio M, Gorelik A, Tee HJ, Wojnar R, Kissane D, Michael N. Methadone versus other opioids for refractory malignant bone pain: a pilot randomised controlled study. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08706-w

BibTeX
@article{Sulistio2024,
  author = {Sulistio, Merlina and Gorelik, Alexandra and Tee, Hoong Jiun and Wojnar, Robert and Kissane, David and Michael, Natasha},
  title = {Methadone versus other opioids for refractory malignant bone pain: a pilot randomised controlled study},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-024-08706-w}
}
Kostenlos starten →